Relationships of Self-Concept, Food and Nutrition Attitudes and Knowledge, and Health Habits to Food Selection and Nutrient Intake

To examine the relationships between self-concept and food- and nutrition-related behavior, information was collected from 153 single women ages 18-35. Participants were contacted through their places of employment and represented a variety of occupations. Each participant had an educational level between a high school diploma and a four-year college degree. Participants completed a questionnaire requesting information about demographic facts, attitudes toward self, attitudes toward the importance of food and nutrition, nutrition knowledge, and health habits. Each participant also completed a three-day food record. Factor analysis of the attitudes toward self, attitudes toward the importance of food and nutrition, and health habits variables yielded 14 meaningful factors. These factors and nutrition knowledge were evaluated for relationships with food selection and nutrient intake. Participants consumed \u3c75% of the Recommended Dietary Allowances (RDA) for energy, calcium, and iron and \u3e125% of the RDA for protein. Snacks were the source of about 17% of calories. Mean score on the 25-point nutrition knowledge test was 14.8 ± 3.6. Scores on one of the factors, Super Person (leader, self-confident, and aggressive) were negatively correlated with 5 of the 15 dietary components studied. Scores on Your Own Thing also were negatively correlated with several dietary components. Scores on the self-perception of a Traditional orientation to life factor (help others and work hard) and the self-perception of being Careful in other health areas factor were positively related to dietary patterns. Scores on the attitude that Nutrition Is Important factor and nutrition knowledge also were positively related to food consumption and nutrient intake

Strategic tradeoffs in competitor dynamics on adaptive networks

Recent empirical work highlights the heterogeneity of social competitions such as political campaigns: proponents of some ideologies seek debate and conversation, others create echo chambers. While symmetric and static network structure is typically used as a substrate to study such competitor dynamics, network structure can instead be interpreted as a signature of the competitor strategies, yielding competition dynamics on adaptive networks. Here we demonstrate that tradeoffs between aggressiveness and defensiveness (i.e., targeting adversaries vs. targeting like-minded individuals) creates paradoxical behaviour such as non-transitive dynamics. And while there is an optimal strategy in a two competitor system, three competitor systems have no such solution; the introduction of extreme strategies can easily affect the outcome of a competition, even if the extreme strategies have no chance of winning. Not only are these results reminiscent of classic paradoxical results from evolutionary game theory, but the structure of social networks created by our model can be mapped to particular forms of payoff matrices. Consequently, social structure can act as a measurable metric for social games which in turn allows us to provide a game theoretical perspective on online political debates.Comment: 20 pages (11 pages for the main text and 9 pages of supplementary material

Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12% to 20% compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners 'eyeball' assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for 'precision medicine'. Yet the inherited genome determines only part of an individual's risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the 'epi'genome. Epigenetic modifications defined as 'heritable changes to the genome that do not involve changes in DNA sequence' have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine

An integrated system for autonomous robotics manipulation

We describe the software components of a robotics system designed to autonomously grasp objects and perform dexterous manipulation tasks with only high-level supervision. The system is centered on the tight integration of several core functionalities, including perception, planning and control, with the logical structuring of tasks driven by a Behavior Tree architecture. The advantage of the implementation is to reduce the execution time while integrating advanced algorithms for autonomous manipulation. We describe our approach to 3-D perception, real-time planning, force compliant motions, and audio processing. Performance results for object grasping and complex manipulation tasks of in-house tests and of an independent evaluation team are presented

The Featureless Transmission Spectra of Two Super-puff Planets

The Kepler mission revealed a class of planets known as "super-puffs," with masses only a few times larger than Earth's but radii larger than Neptune, giving them very low mean densities. All three of the known planets orbiting the young solar-type star Kepler 51 are super-puffs. The Kepler 51 system thereby provides an opportunity for a comparative study of the structures and atmospheres of this mysterious class of planets, which may provide clues about their formation and evolution. We observed two transits each of Kepler 51b and 51d with the Wide Field Camera 3 (WFC3) on the Hubble Space Telescope. Combining new WFC3 transit times with reanalyzed Kepler data and updated stellar parameters, we confirmed that all three planets have densities lower than 0.1 g cm⁻³. We measured the WFC3 transmission spectra to be featureless between 1.15 and 1.63 μm, ruling out any variations greater than 0.6 scale heights (assuming a H/He-dominated atmosphere), thus showing no significant water absorption features. We interpreted the flat spectra as the result of a high-altitude aerosol layer (pressure <3 mbar) on each planet. Adding this new result to the collection of flat spectra that have been observed for other sub-Neptune planets, we find support for one of the two hypotheses introduced by Crossfield & Kreidberg, that planets with cooler equilibrium temperatures have more high-altitude aerosols. We strongly disfavor their other hypothesis that the H/He mass fraction drives the appearance of large-amplitude transmission features

Effect of interleukin-1 beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patients with atherosclerosis who had had a myocardial infarction, were free of previously diagnosed cancer, and had concentrations of high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or greater. To assess dose-response effects, patients were randomly assigned by computer-generated codes to three canakinumab doses (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo. Participants were followed up for incident cancer diagnoses, which were adjudicated by an oncology endpoint committee masked to drug or dose allocation. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT01327846. The trial is closed (the last patient visit was in June, 2017).Baseline concentrations of hsCRP (median 6·0 mg/L vs 4·2 mg/L; p<0·0001) and interleukin 6 (3·2 vs 2·6 ng/L; p<0·0001) were significantly higher among participants subsequently diagnosed with lung cancer than among those not diagnosed with cancer. During median follow-up of 3·7 years, compared with placebo, canakinumab was associated with dose-dependent reductions in concentrations of hsCRP of 26-41% and of interleukin 6 of 25-43% (p<0·0001 for all comparisons). Total cancer mortality (n=196) was significantly lower in the pooled canakinumab group than in the placebo group (p=0·0007 for trend across groups), but was significantly lower than placebo only in the 300 mg group individually (hazard ratio [HR] 0·49 [95% CI 0·31-0·75]; p=0·0009). Incident lung cancer (n=129) was significantly less frequent in the 150 mg (HR 0·61 [95% CI 0·39-0·97]; p=0·034) and 300 mg groups (HR 0·33 [95% CI 0·18-0·59]; p<0·0001; p<0·0001 for trend across groups). Lung cancer mortality was significantly less common in the canakinumab 300 mg group than in the placebo group (HR 0·23 [95% CI 0·10-0·54]; p=0·0002) and in the pooled canakinumab population than in the placebo group (p=0·0002 for trend across groups). Fatal infections or sepsis were significantly more common in the canakinumab groups than in the placebo group. All-cause mortality did not differ significantly between the canakinumab and placebo groups (HR 0·94 [95% CI 0·83-1·06]; p=0·31).Our hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality. Replication of these data in formal settings of cancer screening and treatment is required.Novartis Pharmaceuticals